Manipal Health IPO Reveals Debt Repayment Focus as Acquisition Spree Consumes Over 77% of Rs 8,000 Crore Fresh Issue

Manipal Health IPO Reveals Debt Repayment Focus as Acquisition Spree Consumes Over 77% of Rs 8,000 Crore Fresh Issue​

Manipal Health Enterprises is set to launch a major capital raise with its upcoming Initial Public Offering (IPO). However, the strategic allocation of the fresh issue reveals that the company is prioritizing balance sheet repair over unfettered growth. A substantial portion of the IPO proceeds will be dedicated to settling debt related to an aggressive acquisition spree undertaken by the hospital operator.

The hospital group plans to dedicate a significant amount, Rs 5,552.76 crore, solely toward repaying or prepaying borrowings and accrued interest at its subsidiary Manipal Hospitals Private Limited. This allocation represents 47.47% of Manipal’s consolidated borrowings as of May 31.

Debt Management and IPO Proceeds Allocation​

The total offering for the IPO is projected to raise Rs 9,275 crore, encompassing both existing share sales and the fresh issue. The IPO has been priced in a range of Rs 560-Rs590 per share. Alongside the fresh capital raise, existing shareholders are expected to sell up to 21.61 million shares.

The focus on debt repayment is clear: an additional Rs 574 crore from the IPO will finance the acquisition of another minority stake in Sahyadri Hospitals. Collectively, these two commitments represent a commitment of Rs 6,126.76 crore from the fresh issue, which is set to consume nearly three-quarters of the Rs 8,000 crore earmarked for new capital.

Refinancing Debt-Funded Expansion​

The necessity of this repayment structure stems from a debt-funded expansion model previously employed by Manipal Hospitals. In September 2025, Manipal Hospitals issued 531,000 listed non-convertible debentures, raising Rs 5,310 crore to finance the initial two tranches of the Sahyadri acquisition.

These bonds, which carry a fixed coupon of 9.03% and have a two-year tenure, mandate prepayment if Manipal Health is listed on an Indian stock exchange. The company intends to use the IPO proceeds to redeem the outstanding principal, pay accrued interest, and meet any prepayment penalties during FY27.

The original debt stood at Rs 11,185.02 crore as of May 31. Using the IPO funds to repay this amount is expected to significantly reduce future interest outflow and allow more internal cash flow toward corporate growth initiatives. Manipal estimates a total interest cost of Rs 958.99 crore over the full tenure of these bonds.

The Sahyadri Acquisition Impact on Finances​

The underlying transaction that necessitated much of the debt involved the acquisition of Sahyadri, which provided 10 hospitals and 1,606 licensed beds across several locations in Maharashtra. Manipal Hospitals initially acquired a 78.71% stake in Sahyadri for Rs 4,596.55 crore in October 2025.

The IPO’s commitment to finance the third tranche is completing this continuous expansion, targeting another 9.84% stake at a cost of ₹574 crore. This means the fresh issue is not just retiring acquisition debt but actively fueling the next leg of the same transaction.

Balance Sheet Strain and Revenue Dynamics​

The rapid expansion has already placed considerable strain on Manipal’s balance sheet. Consolidated borrowings increased to Rs 10,553.43 crore as of March 2026 from Rs 4,766.83 crore a year earlier. Furthermore, net debt, including lease liabilities, climbed to 3.74 times adjusted Ebitda from 2 times, according to the prospectus.

The impact on earnings is also visible; while Manipal’s revenue from operations surged 25.4% to Rs 10,335.75 crore in FY26, its profit declined 15.3% to ₹916.52 crore. Finance costs escalated sharply by 69% to reach Rs 864.29 crore during the same period.

Broader Growth Trajectory and Future Plans​

Manipal’s commitment to rapid expansion is historic, having acquired AMRI in September 2023 and Medica Synergie in July 2024 prior to the Sahyadri deal in October 2025. The company's network has grown from 33 hospitals and 9,520 licensed beds in March 2024 to 49 hospitals and 13,037 licensed beds two years later.

Looking ahead, Manipal intends to maintain this growth trajectory post-listing. The strategy includes evaluating acquisitions in new markets, as evidenced by a non-binding term sheet for another hospital in Karnataka entered in June 2026. By 2030, the company plans to add about 483 beds through brownfield projects and an additional 1,943 beds through greenfield developments.